Document is current
Any future updates will be listed below
-
Authors
Corsello, Steven M. http://orcid.org/0000-0002-9929-3709
Nagari, Rohith T.
Spangler, Ryan D.
Rossen, Jordan
Kocak, Mustafa
Bryan, Jordan G. http://orcid.org/0000-0002-4984-0516
Humeidi, Ranad
Peck, David
Wu, Xiaoyun
Tang, Andrew A.
Wang, Vickie M.
Bender, Samantha A.
Lemire, Evan
Narayan, Rajiv
Montgomery, Philip
Ben-David, Uri http://orcid.org/0000-0001-7098-2378
Garvie, Colin W.
Chen, Yejia
Rees, Matthew G. http://orcid.org/0000-0002-2987-7581
Lyons, Nicholas J.
McFarland, James M.
Wong, Bang T.
Wang, Li
Dumont, Nancy
O’Hearn, Patrick J.
Stefan, Eric
Doench, John G. http://orcid.org/0000-0002-3707-9889
Harrington, Caitlin N.
Greulich, Heidi
Meyerson, Matthew http://orcid.org/0000-0002-9133-8108
Vazquez, Francisca
Subramanian, Aravind
Roth, Jennifer A.
Bittker, Joshua A. http://orcid.org/0000-0002-4166-0828
Boehm, Jesse S.
Mader, Christopher C.
Tsherniak, Aviad http://orcid.org/0000-0002-3797-1877
Golub, Todd R. http://orcid.org/0000-0003-0113-2403
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (KL2 TR002542, K08 CA230220, U01 HG008699, U54 HL127366)
Conquer Cancer Foundation
Next Generation Fund at the Broad Institute of MIT and Harvard
Carlos Slim Foundation (Slim Initiative in Genomic Medicine for the Americas
- License Information
-
More Information
Article History
Received: 15 October 2019
Accepted: 6 December 2019
First Online: 20 January 2020
Competing interests
: S.M.C., X.W., H.G., M.M., A.S. and T.R.G. receive research funding unrelated to this project from Bayer HealthCare. M.M. receives research funding from Ono and serves as a scientific advisory board and consultant for OrigiMed. M.M. has patents licensed to LabCorp and Bayer. M.M. and T.R.G. were formerly consultants and equity holders in Foundation Medicine, which was acquired by Roche. J.A.B. is an employee and shareholder of Vertex Pharmaceuticals. J.G.D. and A.T. consult for Tango Therapeutics. T.R.G. is a consultant to GlaxoSmithKline and is a founder of Sherlock Biosciences. Patent applications for the drug uses detailed in this manuscript have been filed. The other authors declare no competing interests.
